Clinical Trials · NCT00688701
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 361
- Start date
- May 2008
- Locations
- 12 sites, 12 countries
- Primary endpoint
- Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12